Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-VEC with Chemotherapy or Endocrine Therapy in HER2-negative Breast Cancer
NCT03554044Phase 1Completed
- Sponsor
- University of California, San Francisco
- Start
- Feb 2020
- Primary completion
- Dec 2023
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of talimogene laherparepvec in breast cancer (2 cohorts), sponsored by University of California, San Francisco. Primary endpoints: Number of patients with treatment-related toxicities by maximum observed grade up to 2.5 years and Maximum tolerated volume up to 2.5 years. Started Feb 2020; status: completed.
02
Drugs
talimogene laherparepvec
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03554044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03554044.